New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
07:37 EDTCGIXCancer Genetics adds additional kidney cancer patent to portfolio
Cancer Genetics announced that the U.S. Patent and Trademark Office has allowed its patent claims related to the company's proprietary methods for detecting the subtype of renal cortical neoplasm present in a patient sample. The patent application is expected to obtain an issued patent number during 2Q14. This latest patent builds on the intellectual property portfolio the company has already gained for kidney cancer diagnostics. New data further validating CGI's UroGenRA Kidney test will be presented on March 3 at the annual U.S. & Canadian Academy of Pathology meeting. In the study, 191 pathology specimens from renal cancer patients were analyzed using CGI's proprietary genomic microarray test, which enables accurate classification of kidney cancer among the four major subtypes and predicts whether the cancer is benign or malignant. The test has been validated to work across sample types ranging from fine-needle aspirate to paraffin-embedded and formalin-fixed tissue, making it widely usable for both new cases as well as cases that are not diagnosable using traditional methods
News For CGIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 12, 2014
07:22 EDTCGIXAssociation of Molecular Pathology is holding annual meeting
2014 Annual Meeting of AMP is being held in National Harbor, Maryland on November 12-15.
November 11, 2014
07:56 EDTCGIXCancer Genetics receives second patent for FHACT
Cancer Genetics announced that it has received a second U.S. patent covering its proprietary FISH-based HPV-Associated Cancer Test, or FHACT, for cervical cancer detection in patients. FHACT is designed to assess change across four biomarkers indicating HPV-associated pre-cancers and cancers. Critically, FHACT can help prevent unnecessary colposcopies and cervical biopsies, reducing costs and complications associated with these invasive procedures.
November 10, 2014
07:58 EDTCGIXCancer Genetics reports adjusted Q3 EPS (41c), consensus (48c)
Reports Q3 revenue $3.22M, consensus $3.18M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use